Navigation Links
GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
Date:8/29/2007

- Text provides cardiologists with an overview of cardiovascular genetics

and genomics -

TORONTO, Aug. 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing patient-friendly blood-based biomarker tests for the detection and staging of virtually any disease or medical condition, today announced that its co-founder and Chief Scientist Dr. C.C. Liew, has co-edited a newly published genomics reference book entitled Cardiovascular Genetics and Genomics for the Cardiologist. The text provides cardiologists with an overview of cardiovascular genetics and genomics, which have been changing the fundamental understanding of cardiovascular disease and the practice of cardiovascular medicine.

"We are very proud of our Chief Scientist and the inventor of our core technologies, Dr. C.C. Liew. This is not only a significant achievement for Dr. Liew, but also an important and notable contribution to both the field of disease-specific genomics and the field of cardiovascular medicine," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "Dr. Liew is truly a pioneer in disease-specific genomics and has earned a global reputation for his outstanding scientific contributions in this cutting-edge area of healthscience."

Dr. Liew currently holds the positions of Visiting Professor of Medicine and Founding Director of the Cardiovascular Genome Unit at Brigham and Women's Hospital, Harvard Medical School, and Professor Emeritus at the University of Toronto. Genetics and Genomics for the Cardiologist is currently available from the publisher, Blackwell Publishing Inc. (http://www.blackwellcardiology.com).

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based biomarker test that can detect colon cancer. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. State technology chief endorses IT audit recommendations
2. Fusion 2007: CA chief says IT complexity raises risk
3. Web-Based Learning Developed under new Chief Education Officer
4. UW computer scientists fighting computer virus "Cold War"
5. UW scientist, former WiCell director found stem cell company
6. Scientists find way to make human collagen in lab
7. Wisconsin scientists to be recognized for innovative biofuel technology
8. UW biophysical scientist honored as society fellow
9. UW scientist wins Pew grant to study little-known immune cells
10. UW-Madison scientists to mimic nature for newest cancer drugs
11. The Scientist magazine names Madison "hotspot" for biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):